It looks like bisantrene may have the potential to be pretty useful in combination with several (many?) other drugs through one or more of:
- anticancer synergy
- reducing resistance
- cardioprotection
Is it possible to license it out to any Pharma who has a drug that would benefit from a combination with bisantrene and license it only for that combination?Allowing Race to sell it multiple times and the buyers to increase the efficacy and extend patent lives of their own drugs?
It looks like bisantrene may have the potential to be pretty...
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
-0.140(7.61%) |
Mkt cap ! $289.4M | |||
| Open | High | Low | Value | Volume |
| $1.88 | $1.89 | $1.70 | $456.4K | 259.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 8662 | 1 |
View Market Depth
| Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
| RAC (ASX) Chart |